Use of Pharmaco-Metabonomics for Early Prediction of Acetaminophen-Induced Hepatotoxicity in Humans
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Achieving the ability to identify individuals who are susceptible to drug-induced liver injury (DILI) would represent a major advance in personalized medicine. Clayton et al. demonstrated that the pattern of endogenous metabolites in urine could predict susceptibility to acetaminophen-induced liver injury in rats. We designed a clinical study to test this approach in healthy adults who received 4 g of acetaminophen per day for 7 days. Urine metabolite profiles obtained before the start of treatment were not sufficient to distinguish which of the subjects would develop mild liver injury, as indicated by a rise in alanine aminotransferase (ALT) to a level more than twice the baseline value (responders). However, profiles obtained shortly after the start of treatment, but prior to ALT elevation, could distinguish responders from nonresponders. Statistical analyses revealed that predictive metabolites included those derived from the toxic metabolite N-acetyl paraquinone imine (NAPQI), but that the inclusion of endogenous metabolites was required for significant prediction. This "early-intervention pharmaco-metabonomics" approach should now be tested in clinical trials of other potentially hepatotoxic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmaco-metabonomic phenotyping and personalized drug treatment
Andrew Clayton, T., Lindon, J. C., Cloarec, O., Antti, H., Charuel, C., Hanton, G., Provost, J.-P., Le Net, J.-L., Baker, D., Walley, R. J., et al. (2006) · Nature · doi:10.1038/nature04648 · Cited by 824
Susceptibility of Human Metabolic Phenotypes to Dietary Modulation
Stella, C., Beckwith-Hall, B., Cloarec, O., Holmes, E., Lindon, J. C., Powell, J., van der Ouderaa, F., Bingham, S., Cross, A. J., & Nicholson, J. K. (2006) · Journal of Proteome Research · doi:10.1021/pr060265y · Cited by 376
Cited by
Graham, G. G., Davies, M. J., Day, R. O., Mohamudally, A., & Scott, K. F. (2013) · Inflammopharmacology · doi:10.1007/s10787-013-0172-x · Cited by 671
Metabolomics enables precision medicine: “A White Paper, Community Perspective”
for “Precision Medicine and Pharmacometabolomics Task Group”-Metabolomics Society Initiative, Beger, R. D., Dunn, W., Schmidt, M. A., Gross, S. S., Kirwan, J. A., Cascante, M., Brennan, L., Wishart, D. S., Oresic, M., et al. (2016) · Metabolomics · doi:10.1007/s11306-016-1094-6 · Cited by 592
“…signature predictive of drug metabolism and development of side effects to acetaminophen—role for gut microbiome Clayton et al. 2006, 2009; Winnike et al. 2010 Metabolomics lipidomics mapping of atypical antipsychotics and baseline signature of response to three…”
BackgroundPharmacogenetics, Pharmacogenomics, and Individualized Medicine
Ma, Q., & Lu, A. Y. H. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003533 · Cited by 464
PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses
Mazaleuskaya, L. L., Sangkuhl, K., Thorn, C. F., FitzGerald, G. A., Altman, R. B., & Klein, T. E. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000150 · Cited by 379
Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives
Fontana, R. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.032 · Cited by 313
Challenges and opportunities of metabolomics
Johnson, C. H., & Gonzalez, F. J. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24002 · Cited by 311
Wang, X., Sun, H., Zhang, A., Sun, W., Wang, P., & Wang, Z. (2011) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2011.01.042 · Cited by 285
Central role of mitochondria in drug-induced liver injury
Pessayre, D., Fromenty, B., Berson, A., Robin, M.-A., Lettéron, P., Moreau, R., & Mansouri, A. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.604086 · Cited by 277
“Preliminary pharmacometabonomic data suggested that patients developing mild transaminase elevations after therapeutic doses of acetaminophen may be those that failed to increase GSH synthesis and metabolite detoxification (Winnike et al., 2010).”
BackgroundXenobiotic Metabolomics: Major Impact on the Metabolome
Johnson, C. H., Patterson, A. D., Idle, J. R., & Gonzalez, F. J. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134748 · Cited by 269
Metabolomics in Toxicology: Preclinical and Clinical Applications
Robertson, D. G., Watkins, P. B., & Reily, M. D. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfq358 · Cited by 211
“The application of metabolomics to predict adverse events early in the dosing, but prior to the occurrence of phenotypic change, was termed ‘‘early intervention pharmaco-metabonomics’’ (Winnike et al., 2010).”
BackgroundMethodSelf-citationPharmacometabolomics: Implications for Clinical Pharmacology and Systems Pharmacology
Kaddurah-Daouk, R., & Weinshilboum, R. M. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.217 · Cited by 188
Meyer, U. A., Zanger, U. M., & Schwab, M. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100502 · Cited by 157
Identification of Differential Responses to an Oral Glucose Tolerance Test in Healthy Adults
Morris, C., O’Grada, C., Ryan, M., Roche, H. M., Gibney, M. J., Gibney, E. R., & Brennan, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072890 · Cited by 88
Wearing, Thinking, and Moving: Testing the Feasibility of Fitness Tracking with Urban Youth
Schaefer, S. E., Ching, C. C., Breen, H., & German, J. B. (2016) · American Journal of Health Education · doi:10.1080/19325037.2015.1111174 · Cited by 82
Pharmacometabonomics and personalized medicine
Everett, J. R., Loo, R. L., & Pullen, F. S. (2013) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563213497929 · Cited by 75
The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment
Moreno-Torres, M., Quintás, G., & Castell, J. V. (2022) · Metabolites · doi:10.3390/metabo12060564 · Cited by 50
21st century toolkit for optimizing population health through precision nutrition
O'Sullivan, A., Henrick, B., Dixon, B., Barile, D., Zivkovic, A., Smilowitz, J., Lemay, D., Martin, W., German, J. B., & Schaefer, S. E. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1348335 · Cited by 36
“One of the first studies to apply phenotyping in this context with human volunteers showed that urinary metabolomic profiles predicted susceptibility to acetaminophen-induced liver injury (Winnike et al., 2009).”
BackgroundCirculating acetaminophen metabolites are toxicokinetic biomarkers of acute liver injury
Vliegenthart, A., Kimmitt, R., Seymour, J., Homer, N., Clarke, J., Eddleston, M., Gray, A., Wood, D., Dargan, P., Cooper, J., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.541 · Cited by 31
“Median (IQR) admission billirubin (lmol/l) 8 (6-15) 5 (5-9) 0.”
Guo, K., & van den Beucken, T. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01317-2 · Cited by 28
Iruzubieta, P., Arias-Loste, M. T., Barbier-Torres, L., Martinez-Chantar, M. L., & Crespo, J. (2015) · BioMed Research International · doi:10.1155/2015/386186 · Cited by 24
Old problem, new solutions: biomarker discovery for acetaminophen liver toxicity
Gloor, Y., Schvartz, D., & F.Samer, C. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1642323 · Cited by 18
“Changes in urinary [108,109] and plasmatic [109] metabolic”
BackgroundAndújar-Vera, F., Alés-Palmer, M. L., Muñoz-de-Rueda, P., Iglesias-Baena, I., & Ocete-Hita, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713562 · Cited by 10
Metadata
- Authors
- Winnike, J. H., Li, Z., Wright, F. A., Macdonald, J. M., O'Connell, T. M., & Watkins, P. B.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2010-02-24
- Volume
- 88
- Issue
- 1
- Pages
- 45-51
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2105479208
- Cited by
- 156
- References
- 2
- FWCI
- 19.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.